Table 1.
Baseline characteristics of the patients according to the use of angiotensin II
| Angiotensin II No angiotensin II P | |||
|---|---|---|---|
| Total number of patients | 46 | 53 | |
| Median age, years (IQR) | 62 (54–69) | 62 (53–68) | 0.653 |
| Sex, male | 41 (89.1) | 42 (79.2) | 0.274 |
| Median body mass index,⁎ kg/m2 (IQR) | 27.7 (25.9–30.5) | 27.7 (24.8–32.3) | 0.910 |
| Healthy weight | 4/28 (14.3%) | 7/34 (20.6%) | 0.427 |
| Overweight | 16/28 (57.1%) | 13/34 (38.2%) | |
| Obesity class 1 | 5/28 (17.9%) | 9/34 (26.5%) | |
| Obesity class 2 | 2/28 (7.1%) | 5/34 (14.7%) | |
| Obesity class 3 | 1/28 (3.6%) | 0/34 (0.0%) | |
| Coexisting disorder | |||
| Hypertension | 19/41 (46.3%) | 23/46 (50.0%) | 0.682 |
| Diabetes | 11/41 (26.8%) | 5/43 (11.6%) | 0.100 |
| Coronary artery disease | 4/41 (9.8%) | 2/45 (4.4%) | 0.418 |
| Cardiac arrhythmias | 3/41 (7.3%) | 4/45 (8.9%) | 0.999 |
| Cerebrovascular disease | 1/41 (2.4%) | 1/44 (2.3%) | 0.999 |
| Chronic respiratory disease† | 1/41 (2.4%) | 0/44 (0.0%) | 0.482 |
| Asthma | 1/41 (2.4%) | 3/44 (6.8%) | 0.617 |
| Chronic obstructive pulmonary disease | 1/41 (2.4%) | 1/44 (2.3%) | 0.999 |
| Chronic neurological disease‡ | 2/40 (5.0%) | 0/44 (0.0%) | 0.224 |
| Moderate/severe chronic kidney disease§ | 3/40 (7.5%) | 3/43 (7.0%) | 0.999 |
| Solid tumour | 2/39 (5.1%) | 1/42 (2.4%) | 0.606 |
| Tobacco smoker | 0.999 | ||
|
1/34 (2.9%) | 1/32 (3.1%) | |
|
2/34 (5.9%) | 1/32 (3.1%) | |
| Medications on chronic use | |||
| Angiotensin–converting enzyme inhibitors | 6/43 (14.0%) | 6/42 (14.3%) | 0.999 |
| Angiotensin II receptor blockers | 6/43 (14.0%) | 6/42 (14.3%) | 0.999 |
| Calcium channel blockers | 6/43 (14.0%) | 2/42 (4.8%) | 0.265 |
| ß–blockers | 8/43 (18.6%) | 6/42 (14.3%) | 0.771 |
| Vitamin K antagonists | 0/43 (0.0%) | 1/43 (2.3%) | 0.999 |
| Novel oral anticoagulants | 1/43 (2.3%) | 0/43 (0.0%) | 0.999 |
| Anti–arrhythmic | 2/43 (4.7%) | 3/43 (7.0%) | 0.999 |
| Aspirin | 10/44 (22.7%) | 5/44 (11.4%) | 0.256 |
| Other antiplatelets | 2/43 (4.7%) | 1/43 (2.3%) | 0.999 |
| Statins | 7/43 (16.3%) | 3/44 (6.8%) | 0.196 |
| Corticosteroids | 0/43 (0.0%) | 3/44 (6.8%) | 0.241 |
| Use of angiotensin II | |||
| Vasopressor | 26 (56.5%) | na | na |
| Low dose | 20 (43.5%) | na | na |
IQR = interquartile range; na = not applicable. Percentages may not total 100 because of rounding.
⁎
Body mass index is calculated dividing the kilograms by the square of the height in meters.
†
Excluding asthma and chronic obstructive pulmonary disease.
‡
Excluding dementia and cerebrovascular disease. § Receiving dialysis, after kidney transplant, uraemia or creatinine > 3 mg/dL